Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justyna Kocik-Krol

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2025
A 3D Co-Culture Model of Endometrial Carcinoma Cells with Peripheral Blood Immune Cells (PBMCs) to Study the Activity of Immune Checkpoint InhibitorsJustyna Kocik-Krol, Marcin Krzykawski
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2025
A PD-1/PD-L1-Sensitive Co-culture-Based Primary T-Cell Activation AssayJustyna Kocik-Krol, Malgorzata Stec, Maciej Siedlar, et al.
International Journal of Molecular Sciences|November 13, 2021
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of ActionEwa Surmiak, Katarzyna Magiera-Mularz, Bogdan Musielak, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for ImmunotherapyAlicja Slota, Katarzyna Golebiowska-Mendroch, Justyna Kocik-Krol, et al.
Molecular Cancer|September 7, 2023
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodiesIsmael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 5, 2025
Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse modelAneta Nieznanska, Malgorzata Statkiewicz, Zuzanna Sandowska-Markiewicz, et al.
Molecules (Basel, Switzerland)|June 10, 2022
Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 InteractionShabnam Shaabani, Louis Gadina, Ewa Surmiak, et al.
Journal of Medicinal Chemistry|July 27, 2021
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein InteractionDamian Muszak, Ewa Surmiak, Jacek Plewka, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for <i>m</i>-Terphenyl DerivativesEwa Surmiak, Julia Ząber, Jacek Plewka, et al.
Anticancer Research|September 30, 2024
Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3D <i>In Vitro</i> CulturesKatarzyna Unrug-Bielawska, David Earnshaw, Magdalena Cybulska-Lubak, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2025
A 3D Co-Culture Model of Endometrial Carcinoma Cells with Peripheral Blood Immune Cells (PBMCs) to Study the Activity of Immune Checkpoint InhibitorsJustyna Kocik-Krol, Marcin Krzykawski
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2025
A PD-1/PD-L1-Sensitive Co-culture-Based Primary T-Cell Activation AssayJustyna Kocik-Krol, Malgorzata Stec, Maciej Siedlar, et al.
International Journal of Molecular Sciences|November 13, 2021
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of ActionEwa Surmiak, Katarzyna Magiera-Mularz, Bogdan Musielak, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for ImmunotherapyAlicja Slota, Katarzyna Golebiowska-Mendroch, Justyna Kocik-Krol, et al.
Molecular Cancer|September 7, 2023
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodiesIsmael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 5, 2025
Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse modelAneta Nieznanska, Malgorzata Statkiewicz, Zuzanna Sandowska-Markiewicz, et al.
Molecules (Basel, Switzerland)|June 10, 2022
Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 InteractionShabnam Shaabani, Louis Gadina, Ewa Surmiak, et al.
Journal of Medicinal Chemistry|July 27, 2021
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein InteractionDamian Muszak, Ewa Surmiak, Jacek Plewka, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for <i>m</i>-Terphenyl DerivativesEwa Surmiak, Julia Ząber, Jacek Plewka, et al.
Anticancer Research|September 30, 2024
Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3D <i>In Vitro</i> CulturesKatarzyna Unrug-Bielawska, David Earnshaw, Magdalena Cybulska-Lubak, et al.
Pageof 2